Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Decitabine + homoharringtonine + cytarabine for relapsed/refractory AML and secondary AML
ChiCTR1800016523Phase 2Not yet recruiting
- Sponsor
- First Affiliated Hospital of Chongqing Medical University
- Start
- Aug 2018
- Modality
- Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of decitabine, homoharringtonine and cytarabine in acute myeloid leukemia (AML), sponsored by First Affiliated Hospital of Chongqing Medical University. Primary endpoints: Bone marrow remission state, Hematologic remission and 4 more. Planned start Aug 2018; status: not yet recruiting.
02
Drugs
decitabinehomoharringtoninecytarabine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on ChiCTR1800016523.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800016523.